India's IPF treatment market, driven by rising fibrotic disease prevalence, enhanced diagnostics, and robust R&D—including novel inhibitors—mirrors global trends of aging demographics, oral therapy preference, hospital dominance, and biologics expansion. More Info: https://www.imarcgroup.com/india-idiopathic-pulmonary-fibrosis-treatment-market